Vestnik On-line
Orenburg State University may 20, 2022   RU/EN
Headings of Vestnik

ЭБС Лань
Лицензия Creative Commons

2012, № 12 (148)

Ulitina A.Yu., Izmaylov A.S. DIFFERENCES IN RESPONSES AT CHOROID NEOVASCULAR MEMBRANES TREATMENT BY RANIBIZUMAB AT WET AGE-RELATED MACULAR DEGENERATION Provided comparative assessment of efficacy of treatment with intravitreal ranibizumab in exudative age related macular degeneration (AMD) depending on the types of choroidal neovascularization (CNV). Predominantly classic CNV has more high treatment density, then occult CNV. In cases of occult CNV are necessary more injections. The results of treatment are worse if patient non-observance recommendation. Absence of state support in respect to patient with exudative AMD is negative factor in functional results of treatment, especially in cases of occult CNV. Key words: choroid neovascularization, subretinal neovascular membrane, angiogenesis inhibitor, age-related macular degeneration, fibrovascular detachment of pigmental epithelium.


1. Astakhov Yu.S., Lisochkina A.B., Shadrichev F.E. Age-related macular degeneration. Clinical recommendations. Ophthalmology / Edited by L.K. moshetova, A.P. Nesterov, E.A.Egorov.– М.: GEOTAR-Media, 2006. — P. 164-188.

2. Kanski D. Acquired diseases of macular area and states connected with them // Clinical ophthalmology: Systemized approach/ Edited by V.P.Erichev.– W.: Elsevier Urban & Partner, 2009. — P. 629.

3. Libman Ye.S., Tolmachev R.A., Shakhova Ye.V. Epidemical characteristic of disability as a result of basic forms of maculopathy// Materials of II Russian seminar "Macular", "round table"/ Edited by Yu.A.Ivanishko. — Rostov on Don, 2006. — P. 15-22.

4. Libman Ye.S., Shakhova Ye.V. State and dynamics of blindness and disability as a result of visual organ pathology in Russia// Theses of reports of VII congress of ophthalmologists of Russia. — М., 2000. — Vol. 2. — P. 209-215.

5. Tishchenko O.E. Pathological retina neovascularisation: modern treatment methods, perspectives// Ophthalmosurgery. — 2010. — №4. — P. 34-39.

6. Bhutto I.A., McLeod D.S., Hasegawa T. et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration// Exp. Eye Res. — 2006. — V. 82, №1. — P. 99-110.

7. Das A., McGuire P.G. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition// Progress in Retinal and Eye Research. — 2003. — V. 22, №– P. 721-748.

8. Dawson D.W., Volpert O.V., Gillis P. et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis// Science. — 1999. — V. 285. — P. 245-248.

9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress// Endocr. Rev. — 2004. — V. 25. — P. 581-611.

10. Funk M., Karl D., Georgopoulos M. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab// Ophthalmol. — 2009. — V. 116, №12. — P. 2393-2399.

11. National Eye Institute. Comparison of AMD Treatment Trials (CATT): Lucentis-Avastin Trial. A multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD). Available at Accessed July 20, 2011.

12. Tezel T.H., Bora N.S., Kaplan H.J. Pathogenesis of age-related macular degeneration// Trends. Mol. Med. — 2004. — V. 10. — P. 417-420.

13. The CATT Research Group. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration// N. Engl. J. Med. — 2011. — V. 364. — P. 1897-1908.

14. Wilson P.W., D'Agostino R.B., Levy D. et al. Prediction of coronary heart disease using risk factor categories// Circulation. — 1998. — V. 97. — P. 1837-1847.

About this article

Authors: Ulitina A.Yu., Izmaylov A.S.

Year: 2012

Sergey Aleksandrovich

© Электронное периодическое издание: ВЕСТНИК ОГУ on-line (VESTNIK OSU on-line), ISSN on-line 1814-6465
Зарегистрировано в Федеральной службе по надзору в сфере связи, информационных технологий и массовых коммуникаций
Свидетельство о регистрации СМИ: Эл № ФС77-37678 от 29 сентября 2009 г.
Учредитель: Оренбургский государственный университет (ОГУ)
Главный редактор: С.А. Мирошников
Адрес редакции: 460018, г. Оренбург, проспект Победы, д. 13, к. 2335
Тел./факс: (3532)37-27-78 E-mail:
1999–2022 © CIT OSU